These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30762364)

  • 1. Shape-Based Generative Modeling for de Novo Drug Design.
    Skalic M; Jiménez J; Sabbadin D; De Fabritiis G
    J Chem Inf Model; 2019 Mar; 59(3):1205-1214. PubMed ID: 30762364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graph-based generative models for de Novo drug design.
    Xia X; Hu J; Wang Y; Zhang L; Liu Z
    Drug Discov Today Technol; 2019 Dec; 32-33():45-53. PubMed ID: 33386094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in de Novo Drug Design: From Conventional to Machine Learning Methods.
    Mouchlis VD; Afantitis A; Serra A; Fratello M; Papadiamantis AG; Aidinis V; Lynch I; Greco D; Melagraki G
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De Novo Molecule Design by Translating from Reduced Graphs to SMILES.
    Pogány P; Arad N; Genway S; Pickett SD
    J Chem Inf Model; 2019 Mar; 59(3):1136-1146. PubMed ID: 30525594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GuacaMol: Benchmarking Models for de Novo Molecular Design.
    Brown N; Fiscato M; Segler MHS; Vaucher AC
    J Chem Inf Model; 2019 Mar; 59(3):1096-1108. PubMed ID: 30887799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design.
    Skalic M; Sabbadin D; Sattarov B; Sciabola S; De Fabritiis G
    Mol Pharm; 2019 Oct; 16(10):4282-4291. PubMed ID: 31437001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generative Recurrent Networks for De Novo Drug Design.
    Gupta A; Müller AT; Huisman BJH; Fuchs JA; Schneider P; Schneider G
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29095571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Generative Models for Molecular Science.
    Jørgensen PB; Schmidt MN; Winther O
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29405647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional Molecular Design with Deep Generative Models.
    Kang S; Cho K
    J Chem Inf Model; 2019 Jan; 59(1):43-52. PubMed ID: 30016587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convolutional neural network based on SMILES representation of compounds for detecting chemical motif.
    Hirohara M; Saito Y; Koda Y; Sato K; Sakakibara Y
    BMC Bioinformatics; 2018 Dec; 19(Suppl 19):526. PubMed ID: 30598075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generative machine learning for de novo drug discovery: A systematic review.
    Martinelli DD
    Comput Biol Med; 2022 Jun; 145():105403. PubMed ID: 35339849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Molecular Design by Combining Deep Autoencoder Recurrent Neural Networks with Generative Topographic Mapping.
    Sattarov B; Baskin II; Horvath D; Marcou G; Bjerrum EJ; Varnek A
    J Chem Inf Model; 2019 Mar; 59(3):1182-1196. PubMed ID: 30785751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the frontier of drug-like chemical space with cutting-edge generative AI models.
    Lavecchia A
    Drug Discov Today; 2024 Sep; 29(9):104133. PubMed ID: 39103144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo molecular design with deep molecular generative models for PPI inhibitors.
    Wang J; Chu Y; Mao J; Jeon HN; Jin H; Zeb A; Jang Y; Cho KH; Song T; No KT
    Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35830870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward efficient generation, correction, and properties control of unique drug-like structures.
    Druchok M; Yarish D; Gurbych O; Maksymenko M
    J Comput Chem; 2021 Apr; 42(11):746-760. PubMed ID: 33583075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists.
    Duan X; Zhang X; Xu B; Wang F; Lei M
    Chem Biol Drug Des; 2016 Jul; 88(1):142-54. PubMed ID: 26851125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNMG: Deep molecular generative model by fusion of 3D information for de novo drug design.
    Song T; Ren Y; Wang S; Han P; Wang L; Li X; Rodriguez-Patón A
    Methods; 2023 Mar; 211():10-22. PubMed ID: 36764588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep reinforcement learning for de novo drug design.
    Popova M; Isayev O; Tropsha A
    Sci Adv; 2018 Jul; 4(7):eaap7885. PubMed ID: 30050984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo design with deep generative models based on 3D similarity scoring.
    Papadopoulos K; Giblin KA; Janet JP; Patronov A; Engkvist O
    Bioorg Med Chem; 2021 Aug; 44():116308. PubMed ID: 34280849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico identification of bioisosteric functional groups.
    Ertl P
    Curr Opin Drug Discov Devel; 2007 May; 10(3):281-8. PubMed ID: 17554854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.